INmune Bio
(NASDAQ:INMB)
$11.63
0[0.00%]
At close: Mar 27
$11.63
0[0.00%]
After Hours: 4:00PM EDT
Q4 2023 earnings were released today after the market close
Today's conference call ended over 5 hours ago Click to view the webcast
Consensus Rating1
Buy
Highest Price Target1
$29.00
Lowest Price Target1
$7.00
Consensus Price Target1
$16.50

INmune Bio Stock (NASDAQ:INMB), Analyst Ratings, Price Targets, Predictions

INmune Bio Inc has a consensus price target of $16.5, established from looking at the 5 latest analyst ratings. The last 3 analyst ratings were released from Baird, BTIG, and B. Riley Securities on June 1, 2023, May 24, 2022, and May 24, 2022. With an average price target of $12.33 between Baird, BTIG, and B. Riley Securities, there's an implied 6.05% upside for INmune Bio Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Feb
0
0
0
0
0
Jan
0
0
0
0
0
Dec 23
0
0
0
0
0
Nov 23
0
0
0
0
0
Oct 23
0
0
0
0
0
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Baird
BTIG
B. Riley Securities
B. Riley Securities

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for INmune Bio

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
06/01/2023INMBBuy Now
INmune Bio
$11.6337.58%Baird
Joel Beatty
→ $16Initiates → OutperformGet Alert
05/24/2022INMBBuy Now
INmune Bio
$11.6320.38%BTIG
Thomas Shrader
$31 → $14MaintainsBuyGet Alert
05/24/2022INMBBuy Now
INmune Bio
$11.63-39.81%B. Riley Securities
Mayank Mamtani
$14 → $7DowngradeBuy → NeutralGet Alert
01/24/2022INMBBuy Now
INmune Bio
$11.6371.97%B. Riley Securities
Mayank Mamtani
$32 → $20MaintainsBuyGet Alert
04/21/2021INMBBuy Now
INmune Bio
$11.63149.36%B. Riley SecuritiesInitiates → BuyGet Alert

FAQ

Q

What is the target price for INmune Bio (INMB)?

A

The latest price target for INmune Bio (NASDAQ: INMB) was reported by Baird on June 1, 2023. The analyst firm set a price target for $16.00 expecting INMB to rise to within 12 months (a possible 37.58% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for INmune Bio (INMB)?

A

The latest analyst rating for INmune Bio (NASDAQ: INMB) was provided by Baird, and INmune Bio initiated their outperform rating.

Q

When was the last upgrade for INmune Bio (INMB)?

A

There is no last upgrade for INmune Bio.

Q

When was the last downgrade for INmune Bio (INMB)?

A

The last downgrade for INmune Bio Inc happened on May 24, 2022 when B. Riley Securities changed their price target from $14 to $7 for INmune Bio Inc.

Q

When is the next analyst rating going to be posted or updated for INmune Bio (INMB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of INmune Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for INmune Bio was filed on June 1, 2023 so you should expect the next rating to be made available sometime around June 1, 2024.

Q

Is the Analyst Rating INmune Bio (INMB) correct?

A

While ratings are subjective and will change, the latest INmune Bio (INMB) rating was a initiated with a price target of $0.00 to $16.00. The current price INmune Bio (INMB) is trading at is $11.63, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch